This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.
Amgen launched its Kamjinti there in July, with Biocon and Mylan reaching the market with their Ogivri biosimilar in December, and others are in the latter stages of regulatory review.
Mylan and Biocon have launched their biosimilar Herceptin (trastuzumab) under the brand name Ogivri, after Roche tried and failed to get an injunction on sales of biosimilars in the US. . ... Mylan/Biocon’s Herceptin biosimilar is the second to
of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.
Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
The companies will develop multiple immunology and oncology biosimilars. Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to ... globally”. The deal with Novartis' subsidiary Sandoz
The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the
More from news
Approximately 10 fully matching, plus 25 partially matching documents found.
Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....